Oncology Innovations: Novel Approaches to Immunotherapy in mESCC

Released On
August 20, 2021

Expires On
August 19, 2022

Media Type

Completion Time
30 minutes

Gastroenterology, Hematology-Oncology

Gastric Cancer

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Postgraduate Institute for Medicine and DKBmed, LLC.

This activity is supported by an independent educational grant from Merck & Co., Inc.

Credit Available

  • Physicians — maximum of 0.5 AMA PRA Category 1 Credit(s)
  • Nurses — 0.5 Contact Hours
  • Physician Assistants — 0.5 AAPA Category 1 CME credit

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the educational needs of medical oncologists, gastroenterologists, and other HCPs who treat patients with esophageal carcinoma.

Program Overview

This activity will cover the advances in the therapeutic paradigm for patients with esophageal carcinoma in a digital, interactive infographic format.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Develop treatment strategies for patients with metastatic esophageal squamous cell carcinoma who do not respond to chemotherapy and who are not candidates for surgery.  
  • Demonstrate the appropriate role of biomarker testing in developing treatment plans for patients with esophageal squamous cell carcinoma.  
  • Recall relevant clinical trial data for immunotherapeutic agents used in treating patients with advanced esophageal squamous cell carcinoma. 
  • Analyze treatment options based on potential adverse events for patients with esophageal squamous cell carcinoma.




Yelena Janjigian, MD

Associate Professor and Chief of Gastroenterology Oncology Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY


Accreditation Statement

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and DKBmed, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Credit Designation

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.

Continuing Physician Assistant Education

Postgraduate Institute for Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until August 19, 2023. PAs should only claim credit commensurate with the extent of their participation.


Disclosures of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Yelena Janjigian

  • Consulting Fees: Bristol-Myers Squibb, Merck Serono, RGENIX, Daiichi-Sankyo, Pfizer, Bayer, Imugene, Merck, Zymeworks, Seattle Genetics, Basilea Phamaceutica, AstraZeneca
  • Contracted Research: NCI, Dept of Defense, Cycle for Survical, Fred’s Team, RGENIX, Bayer, Genentech/Roche, Bristol-Myers Squibb, Eli Lilly, Merck
  • Ownership Interest: RGENIX

The PIM and DKB planners and others have nothing to disclose.

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Submit the evaluation form.
Certificates will be emailed to the participant

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

Postgraduate Institute for Medicine requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.


This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Contact Information

For CME questions please contact: inquiries@pimed.com